Daiichi Sankyo Co Ltd 2018 IR
The report highlights Daiichi Sankyo's progress toward its 2025 Vision of becoming a Global Pharma Innovator with a competitive advantage in oncology. In fiscal 2017, the company achieved the No. 1 ranking in domestic pharmaceutical revenue in Japan for the second consecutive year. It also advanced its oncology pipeline, particularly the antibody-drug conjugate franchise led by DS-8201. On the environmental front, the company reduced its global CO2 emissions by 7.1% compared to fiscal 2015, aligning with its Science Based Targets commitment.
Company: Daiichi Sankyo Co Ltd
Sector: Health Care
Country: Japan
Year: 2018
Type: IR
Pages: 62
Daiichi Sankyo Co Ltd
Value Report
The report highlights Daiichi Sankyo's progress toward its 2025 Vision of becoming a Global Pharma Innovator with a competitive advantage in oncology. In fiscal 2017, the company achieved the No. 1 ranking in domestic pharmaceutical revenue in Japan for the second consecutive year. It also advanced its oncology pipeline, particularly the antibody-drug conjugate franchise led by DS-8201. On the environmental front, the company reduced its global CO2 emissions by 7.1% compared to fiscal 2015, aligning with its Science Based Targets commitment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees